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Angioedema is a sudden, transient swelling of well-demarcated areas of the dermis, subcutaneous tissue, mucosa,
and submucosal tissues that can occur with or without urticaria. Up to 25% of people in the US will experience an
episode of urticaria or angioedema during their lifetime, and many will present to the emergency department with
an acute attack. Most cases of angioedema are attributable to the vasoactive mediators histamine and bradykinin.
Histamine-mediated (allergic) angioedema occurs through a type I hypersensitivity reaction, whereas
bradykinin-mediated (non-allergic) angioedema is iatrogenic or hereditary in origin.
Although their clinical presentations bear similarities, the treatment algorithm for histamine-mediated angioedema
differs significantly from that for bradykinin-mediated angioedema. Corticosteroids, and epinephrine are effective in
the management of histamine-mediated angioedema but are ineffective in the management of
bradykinin-mediated angioedema. Recent advancements in the understanding of angioedema have yielded
pharmacologic treatment options for hereditary angioedema, a rare hereditary form of bradykinin-mediated
angioedema. These novel therapies include a kallikrein inhibitor (ecallantide) and a bradykinin β2 receptor
antagonist (icatibant). The physician’s ability to distinguish between these types of angioedema is critical in
optimizing outcomes in the acute care setting with appropriate treatment. This article reviews the pathophysiologic
mechanisms, clinical presentations, and diagnostic laboratory evaluation of angioedema, along with acute
management strategies for attacks.Review
Up to 25% of people in the US will experience an episode
of urticaria, angioedema, or both at some point during
their lifetime. It is estimated that each year more than 1
million patients present to a physician with signs or
symptoms of urticaria or angioedema, many of whom
present to the emergency department with an acute at-
tack [1-3]. Symptoms of urticaria are similar to those of
allergic angioedema and may be a component of ana-
phylaxis [1,4].
Although both urticaria and allergic angioedema are
mediated by the activation of mast cells, there are many
differences between the two conditions. Unlike angioe-
dema, urticaria rarely affects mucosal tissue. Urticarial* Correspondence: Jonathan.Bernstein@uc.edu
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reproduction in any medium, provided the origwheals involve both the mid- and papillary dermis,
whereas angioedema involves the reticular (deep) dermis
and subcutaneous and submucosal tissues. Isolated
angioedema can sometimes manifest with symptoms of
pain and tenderness, whereas itching can be present with
or without urticaria in patients with angioedema [3,5].
Angioedema is a presenting sign that results from an
underlying pathophysiologic process involving the loca-
lized or systemic release of one of several vasoactive
mediators, most frequently histamine or bradykinin.
Angioedema resulting from the biochemical cascade
initiated by the release of bradykinin is distinct from that
caused by histamine release; however, the resulting
clinical signs and symptoms may be quite similar. Both
mediators induce vascular leakage and consequent non-
pitting interstitial edema, which results in transient swel-
ling of well-demarcated areas. Although angioedema may
occur at any site of the body, it most commonly involvesger. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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along with the subglottal, abdominal, and genital areas
[1,3,6,7].
Angioedema can progress rapidly, and cases that in-
volve the mouth, tongue, larynx, lips, or face constitute a
medical emergency. Swelling of these tissues can occur
in a matter of minutes in the case of histamine-mediated
angioedema compared with a typical slower onset with
bradykinin-mediated angioedema. However, both forms
of angioedema can lead to imminent airway obstruction
and a life-threatening emergency. Thus, emergency phy-
sicians must have a basic understanding of the pathophy-
siologic processes involved in acute angioedema. This
review focuses on angioedema induced by histamine or
bradykinin release, and not pseudoallergic and idiopathic
angioedema, which are discussed only briefly [1].Forms of angioedema
Histamine-mediated angioedema occurs through an
allergic mechanism, specifically a type I hypersensitivity
reaction, which occurs after a patient has had prior
“sensitization” to a particular antigen. Upon re-exposure
to that antigen, mast cells are activated and release pre-
formed mediators such as histamine and newly formed
mediators such as leukotrienes. Increased concentrations
of histamine and these other bioactive mediators are re-
sponsible for the characteristic edema and swelling that
occur during an acute attack.
In general, non–histamine-mediated angioedema occurs
through the increased production of bradykinin due to a
lack of regulation of the contact pathway, ultimately leading
to edema. Bradykinin-mediated angioedema is divided into
three distinct types: hereditary angioedema (HAE),
angiotensin-converting enzyme inhibitor (ACEI)-induced
angioedema, and acquired angioedema (AAE) [1].
Similarities between the clinical presentations of differ-
ent types of angioedema complicate their management.
Although diagnostic blood tests can be very helpful in
differentiating between the different types of angioe-
dema instigating an acute attack, performing these tests
takes time and results usually cannot be obtained im-
mediately during the acute emergency treatment of an
attack. In such cases, achieving a positive clinical out-
come depends heavily on the clinician’s ability to dis-
tinguish among the different types of angioedema at
the bedside through a comprehensive history and phys-
ical examination [8].
Importantly, other forms of angioedema exist that are
relatively rare, do not occur through an allergic mechan-
ism, and are provoked by the release of a vasoactive me-
diator other than histamine or bradykinin. These other
forms include pseudoallergic angioedema (PAE) and
idiopathic angioedema (IAE) [1].PAE is a form of drug-induced, non-allergic angioe-
dema, and its pathogenesis is related to the mechanism
of action of the inciting medication. One example of PAE
is the allergic reaction to aspirin and nonsteroidal anti-
inflammatory drugs (NSAIDs), where severe broncho-
constriction, severe laryngeal angioedema, urticaria, or
shock occurs within 3 to 4 h of ingestion of the drug.
PAE in response to aspirin is thought to occur through
the inhibition of cyclooxygenase and consequent gener-
ation of cysteinyl leukotrienes, which serve as mediators
for the resultant angioedematous reaction [1,9].
IAE, which is not well understood, is a diagnosis of ex-
clusion assigned to cases of recurrent angioedema for
which no exogenous agent or underlying genetic abnor-
mality can be identified. Some authors have included
urticaria-associated angioedema in this category, while
others have restricted the diagnosis of IAE to patients
with recurrent angioedema without urticaria [10].
Pathophysiology of angioedema
In general, the pathophysiology of angioedema involves
a sudden increase in the permeability of vessel walls in
the skin and submucosa. This increased permeability
permits local extravasation of plasma and consequent
tissue swelling [5].
Histamine-mediated angioedema
Histamine-mediated or allergic angioedema occurs
through a type I IgE-mediated hypersensitivity immune
response, which is largely mast cell-dependent. Genetic-
ally susceptible individuals with prior exposure to an
offending allergen become “sensitized.” Sensitization
occurs when the allergen is taken up by antigen-
presenting cells (i.e., dendritic cells, macrophages, or B
cells) and is broken down into small peptides (9–11
amino acids in length). The relevant peptides are then
presented to the cell surface in conjunction with major
histocompatibility class 2 (MHC2) antigens. This
MCH2 peptide complex is recognized by T-helper
lymphocyte receptors and a number of other co-
stimulatory molecules, resulting in T-cell activation and
the release of Th2 cytokines, including interleukin (IL)-
4, IL-5, and IL-13, that promote increased production
of IgE and the differentiation and migration of eosino-
phils, in addition to many other functions leading to al-
lergic inflammation. These cytokines also cause B
lymphocytes to differentiate into plasma cells that pro-
duce specific IgE antibodies that specially recognize the
original sensitizing antigenic peptide. These specific
antibodies bind to high-affinity IgE receptors (FcεR-1)
and can persist on these receptors for months or years.
Upon re-exposure to the inciting agent, the allergenic
peptide is recognized by the antigen-binding sites of
the specific IgE antibodies bound to the high-affinity
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that result in activation of the mast cell and the release
of preformed and newly formed bioactive mediators
(Figure 1) [4]. These mediators, such as histamine, can
then bind to selective receptors (i.e., H1 receptors) on
the vascular endothelium, leading to vasodilation and
increased permeability [4,11].
Bradykinin-mediated angioedema
Kinins are a group of pharmacologically active peptides
that are released into body fluids and tissues following
the enzymatic action of kallikreins on kininogens, which
occurs through a complex proteolytic cascade of events
called the kallikrein-kinin cascade (Figure 2). The
kallikrein-kinin cascade, also referred to as the “contact
activation pathway” or intrinsic pathway, is initiated
when factor XII (Hageman factor) binds to damaged tis-
sue, becoming activated through conversion to factor
XIIa. Factor XIIa converts prekallikrein to plasma kallik-
rein, and these two proteins autoactivate each other
through a positive feedback loop. Plasma kallikrein then
cleaves high-molecular-weight kininogen (HMWK),
thereby liberating bradykinin [12]. The binding of brady-
kinin to bradykinin β2 receptors induces vasodilation
and increased endothelial permeability, yielding the
characteristic signs and symptoms of an acute attack of
angioedema [1,13].
Hereditary angioedema HAE is a rare (1:10,000-
1:50,000 prevalence), autosomal dominant disorder char-
acterized by a quantitative (type I) or qualitative (type II)
deficiency of C1 esterase inhibitor (C1-INH) due to a mu-
tation of the C1-INH SERPING1 gene, located on chromo-
some 11q. HAE with normal C1-INH (type III) occurs












Figure 1 Type I hypersensitivity is mediated by IgE and induces
mast cell degranulation. FcεRI, high-affinity IgE receptor; IgE,
immunoglobulin E; IL-4, interleukin 4; IL-5, interleukin 5; TNF-α,
tumor necrosis factor-alpha [4].factor XII [10,13,14]. Because C1-INH is a key inhibitor of
three enzymes in the kallikrein-kinin cascade—factor XIIa,
factor XIIf, and plasma kallikrein—deficiency of functional
C1-INH in patients with HAE results in the uncontrolled
activation of the entire cascade [13].
In an acute attack of HAE, relative overactivation of
the kallikrein-kinin cascade generates excessive bradyki-
nin. Consequently, the vasodilator properties of bra-
dykinin augment vascular permeability, eliciting the
characteristic HAE symptoms of localized swelling, in-
flammation, and pain (Figure 3) [12].
ACE inhibitor-induced angioedema
Angiotensin-converting enzyme plays a major role in the
renin-angiotensin-aldosterone system, through two pro-
teolytic mechanisms: conversion of angiotensin I to
angiotensin II and degradation of bradykinin. These two
actions make ACE inhibition a chief target in the treat-
ment of hypertension, myocardial infarction (MI), heart
failure, and type I diabetic nephropathy. Treatment with
an ACEI following MI improves survival, rate of
hospitalization, symptoms, and cardiac performance; in
addition to the low cost of these agents, these factors ac-
count for the widespread use of ACEIs [15,16].
ACEI-induced angioedema is associated with the re-
duction in bradykinin degradation that is caused by
ACEIs. As in HAE, increased levels of bradykinin lead to
the symptoms of swelling, pain, and inflammation that
are seen in patients who present with an acute attack.
ACEI-induced angioedema most often involves the head,
neck, face, lips, tongue, and larynx. Rarely, it involves
visceral organs. Life-threatening edema of the upper air-
way presents in 25-39% of cases of ACEI-induced
angioedema. Although studies have noted that ACEI-
induced angioedema most commonly occurs shortly
after treatment is initiated, it can develop long after
treatment has started [17]. Interestingly, angiotensin re-
ceptor blockers (ARBs), also referred to as AT1-receptor
antagonists or blockers, appear to induce angioedema at
a lower frequency than do ACEIs [1]. When ACE activ-
ity is inhibited, the enzyme aminopeptidase P (APP)
metabolizes bradykinin. Bradykinin amasses during ACE
inhibition in individuals who have subnormal activity of
APP due to a genetic mutation in a gene-encoding
membrane–bound APP [12].
Acquired angioedema The prevalence of AAE is
believed to be 1:100,000 to 1:500,000, and it primarily
affects adults and the elderly. AAE results from a non-
genetic C1-INH deficiency. Ten to fifteen percent of
patients have an underlying lymphoproliferative dis-
order; therefore, screening these patients with blood
tests and possibly bone marrow biopsy to exclude malig-
nancy is recommended. Many of these patients may also
Negative surface exposed by
















































Figure 2 Kallikrein-kinin cascade. During an acute HAE attack, reduced activity of C1 esterase inhibitor (C1-INH) results in overactivation of the
kallikrein-kinin cascade and subsequent production of bradykinin. Bradykinin is the likely mediator of the vasodilation, edema, and pain that
characterize acute HAE attacks. HMWK, high-molecular-weight kininogen; IL, interleukin; MASP, MBP-associated serine protease; MBP, mannose-
binding protein; TNF-α, tumor necrosis factor-alpha.
Contact system





























Figure 3 The contact, complement, and fibrinolytic systems. C1-INH, C1 esterase inhibitor. Republished with permission from [37].
[PERMISSION PENDING].
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underlying lymphoproliferative disorder and/or the C1-
INH autoantibody can be curative [18].Clinical manifestation of angioedema
Patients with angioedema may present with or without
urticaria [8]. Angioedematous lesions tend to be non-
pitting and non-pruritic. Despite their non-pruritic na-
ture, these lesions can invoke significant sensations of
pain and burning [7]. Although they do not in them-
selves appear desquamated or discolored, the pruritic
component of angioedematous lesions may cause
scratching or rubbing, with resultant discoloration [6].Histamine-mediated angioedema
Some of the classic signs associated with histamine-
mediated angioedema are the “wheal and flare” reaction
of the superficial layers of the skin and interstitial edema
of underlying subcutaneous, mucosal, and submucosal
layers of the skin [4]. These reactions therefore fre-
quently manifest as pruritic hives with or without
angioedema. Also of importance is the evanescent nature
of these attacks in contrast to non-histamine-mediated
angioedema. Acute attacks of urticaria and/or angioe-
dema are typically self-limited; swelling typically lessens
or resolves over the course of 24 h. Not infrequently,Table 1 Clinical and diagnostic features of various types of an
Angioedema type Clinical and diagnostic features
Histamine-mediated
Allergic angioedema Angioedema usually accompanied by urticari
to allergens; attacks last for 24–48 h; responsi
Angioedema with urticarial
vasculitis




types I and II
Recurrent attacks without urticaria; erythema




Associated with mutations in factor XII; more
childhood; face, tongue, extremity involveme
cardinal symptom; more disease-free intervals
unresponsive to antihistamines or corticostero




History of ACE inhibitor use; no urticaria; face
patients usually can tolerate ARBs
Not mediated by histamine or bradykinin
Idiopathic angioedema Angioedema sometimes accompanied by urt
responsive to antihistamines or corticosteroid
Pseudoallergic angioedema Urticaria typically present; usually class-specifi
NSAID-induced angioedema, which occurs be
leukotrienes
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, NSAID nonsthese reactions can be recurring, and when they persist
for more than 6 weeks are considered chronic [5].
Although histamine-mediated attacks of angioedema
most commonly occur in hyperallergic or atopic indivi-
duals (i.e., patients with allergic rhinitis, extrinsic asthma,
or atopic dermatitis/eczema), attacks induced by a food
or medication may be seen in the absence of atopy. In
addition to acute swelling and edema, allergic angioe-
dema always involves a recognizable trigger, most com-
monly insect stings, food, or medications [10].
Angioedema that is mediated by histamine typically
responds to antihistamines (Table 1). Swelling can occur
at any site of the body, but histamine-mediated angioe-
dema has a predilection for the facial area, particularly
the lips and periorbital area and, less commonly, the
genitalia. Isolated allergic angioedema may involve the
throat or larynx, resulting in dyspnea or stridor caused
by laryngeal edema. In some instances, patients can pro-
gress to anaphylaxis, a potentially fatal systemic allergic
reaction [4]. Anaphylaxic manifestations can include dif-
fuse hives, angioedema, gastrointestinal symptoms, and
hypotension. In its most severe form, loss of conscious-
ness due to vascular collapse may occur [4]. Pulmonary
symptoms, including hyperinflation, peribronchial con-
gestion, submucosal edema, edema-filled alveoli, and eo-
sinophilic infiltration are often noted during anaphylaxis
[4]. Although these cases are responsive to antihistaminegioedema
a and sometimes anaphylaxis; may be pruritic; associated with exposure
ve to antihistamines or corticosteroids
may be petechiae or purpura after swelling resolves; symptoms of
marginatum is a cardinal finding; onset in childhood or young
ry in 75% of patients; attacks unresponsive to antihistamines or
common in women; may be estrogen dependent; typical onset after
nt is more frequent than abdominal; recurrent tongue swelling is
than in HAE types I and II; family history of angioedema; attacks
ids
r later; no family history; attacks unresponsive to antihistamines or
and tongue most frequent sites; more common in blacks and smokers;
icaria; swelling may persist for up to 48 h; attacks may occur daily;
s
c reaction; thought to be mediated by cysteinyl-leukotrienes; includes
cause of cyclooxygenase inhibition and subsequent release of cysteinyl-
teroidal anti-inflammatory drug.
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patients and/or physicians implicate a food or drug as
the trigger without adequately proving cause and effect,
which can lead to erroneous elimination of important
medications or unnecessarily restrictive diets. Therefore,
once stabilized, these patients should be evaluated by a
physician experienced in the management of urticaria/
angioedema to establish whether these reactions are sec-
ondary to a specific cause or are idiopathic, as the latter
is often the case.
HAE type III HAE type III was first used to describe a
group of women who presented with angioedema similar
to that seen with HAE types I and II but without any
complement abnormalities. Patients with HAE type III
more commonly experience angioedema in the facial re-
gion involving the tongue, and lips; in severe cases, they
may develop laryngeal edema. Prodromes such as ery-
thema marginatum have not been commonly observed
in HAE type III patients [7].
Patients diagnosed with HAE type III usually manifest
symptoms later in life and have a well-defined gener-
ational history of angioedema (Table 1). A recent study
found the mean age of symptom onset for HAE type III
to be 26.8 years (SD ± 14.9 years, range = 1–68 years).
Another characteristic of this form of angioedema is that
it is frequently exacerbated by estrogen surges during
pregnancy or by treatment with oral contraceptives and
hormonal replacement therapy [19]. The original de-
scription of this variant form of HAE was in a family
where a gain-of-function mutation in factor XII was
observed [20]. However, subsequent investigations of this
mutation in other cases of HAE type III have not yielded
similar findings, and as of yet the underlying genetic and
mechanistic cause of this condition is unknown.
The clinical course of patients with HAE type III typ-
ically differs from HAE types I and II in that they have
more disease-free intervals during the course of disease.
There is still a great deal of uncertainty regarding how
to definitively diagnose and treat this condition.
Bradykinin-mediated angioedema, HAE types I and II
The most frequently encountered symptoms in HAE
types I and II (HAE due to C1-INH deficiency) are skin
edema, abdominal pain, and life-threatening laryngeal
edema. Skin swelling occurs most commonly in the ex-
tremities and less frequently involves the face and other
body sites. Abdominal attacks, which are also very
prevalent in these patients, are caused by transient
edema of the bowel wall and manifest with significant
pain, vomiting, and diarrhea due to partial or complete
intestinal obstruction, ascites, and hemoconcentration.
In up to one-third of patients, erythema marginatum,
which is a serpiginous erythematous non-pruritic rash,can manifest before the onset of an attack in patients
with either type I or type II HAE; however, urticaria and
pruritus are not typically associated with these two types
of HAE (Table 1) [7,10].
A recent analysis of 195 patients with HAE found
that 54% experienced an average of more than 12
attacks per year; symptom-free years were rare, repre-
senting only 370 (6.5%) of the 5,736 patient-years
included in the analysis [19]. Although clinical presen-
tation varies, HAE types I and II often present during
childhood (Table 1). Most patients experience progres-
sive worsening of symptoms over several hours; these
episodes can be quite protracted, lasting from 2 to 5
days without treatment [20].
ACE inhibitor-induced angioedema
ACEI-induced angioedema occurs in 0.1-0.7% of
patients treated with these agents. The incidence of
ACEI-induced angioedema appears to be highest (25%)
during the first month of treatment [21] but can occur
from months to years after the initiation of treatment.
Less commonly, ACEI-induced angioedema has been
associated with medications such as NSAIDs—via in-
hibition of the COX enzyme pathway leading to
changes in prostaglandin synthesis [5,11]—and alteplase
[22]. Although rare, angioedema can also be induced
by ARBs; for the most part, ARBs are considered safe
for use by patients who have a history of ACEI-
induced angioedema [21].
ACEI-induced angioedema is not associated with urti-
caria [8,23] and most commonly involves the tongue,
lips, and face [21]. ACEI-induced angioedema appears to
be four to five times more common in African-
American than in Caucasian individuals [21] owing to
genetic polymorphisms in APP, a critical enzyme for me-
tabolizing ACEIs.
Acquired angioedema
The presentation of AAE is, broadly speaking, similar to
that of HAE types I and II, with recurrent attacks of sub-
cutaneous and/or submucosal swelling without urticaria.
As mentioned, AAE is much less common than HAE,
affecting approximately one-tenth as many patients. Clinical
characteristics that differentiate this form of angioedema
from HAE are older age (the typical patient is elderly) and
the absence of a family history of angioedema [23].
Differential diagnosis of angioedema
Angioedema is a clinical sign that may be associated with
one of several different clinical conditions. In addition to al-
lergic and non-allergic angioedema, in the differential diag-
nosis for angioedema the following should be ruled out:
facial cellulitis, acute contact dermatitis, photodermatitis,
Crohn’s disease (particularly if the lips and mouth are
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tumid discoid lupus erythematosus, Ascher syndrome,
Melkersson-Rosenthal syndrome, and superior vena cava
syndrome [5].Laboratory evaluation of angioedema
A possible algorithm is presented for the diagnostic
workup patients with suspected non-allergic angioedema
(Figure 4) [8] or HAE (Figure 5) [24].C4 level WNL
HAE unlikely: consider other















Stop all medications known 
such as ACE inhibitors, 
Measure the C4 complem
screen for C1-INH
Figure 4 Diagnostic considerations in patients who present with non
nonsteroidal anti-inflammatory drugs; C1-INH, C1 esterase inhibitor; HAE, he
with permission. [PERMISSION PENDING].Histamine-mediated angioedema
A definitive diagnosis of histamine-mediated angioedema
can be achieved through laboratory evaluation for mar-
kers of mast cell degranulation (elevated urine histamine
and serum tryptase levels) (Table 2). Prick skin testing or
serum-specific IgE assays may be appropriate if the his-
tory is suggestive of sensitization to a suspected allergen
such as a food. If laboratory test results for urine hista-
mine and serum tryptase levels are unavailable, the diag-
nosis relies on history and clinical presentation [21].in
t
C1-INH level and function
below normal range







HAE likely: confirm the diagnosis by
measuring the C1-INH in serum by







ent level in serum to
 deficiency
allergic angioedema. ACE, angiotensin-converting enzyme; NSAIDs,
reditary angioedema; WNL, within normal limits. Modified from [8];
Consider hereditary angioedema:
- Recurrent angioedema (without urticaria)
- Recurrent episodes of abdominal pain and vomiting
- Laryngeal edema
- Positive family history of angioedema
Measure: serum C4,
C1-INH antigenic protein,
C1-INH functional level if available
C4 quantity low but
C1-INH protein normal
or elevated
C4 and C1-INH protein 
quantities decreased
C4, C1-INH protein 
normal
Determine C1-INH 
function and repeat C4
and C1-INH protein levels
Confirm decreased 






















Confirm C4, C1-INH 
normal during attack
Consider angioedema
types other than HAE


















Figure 5 International consensus algorithm for the diagnosis of hereditary angioedema. ACE, angiotensin-converting enzyme; C4,
complement factor 4; C1-INH, C1 esterase inhibitor; HAE, hereditary angioedema. Modified from [24]; with permission. [PERMISSION PENDING].
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In patients with HAE Type III, the level and function of
C1-INH are normal. The serum C4 level is also normal
(Table 2) [8].
Bradykinin-mediated angioedema: HAE types I and II
Because the clinical signs and symptoms of HAE types I
and II are very similar, distinguishing between the tworequires laboratory evaluation. In HAE type I, the serum
C4 level is decreased during and between attacks, and
the serum C1-INH level is decreased and sometimes un-
detectable. In HAE type II, the serum C4 level is
decreased during and between attacks, while the serum
C1-INH level is within normal limits or even increased,
but C1-INH is functionally deficient (Table 2, Figures 4
and 5) [8]. Typically, in type II, the serum C2 level is















Histamine-mediated angioedema ↑ ↑ NL NL NL NL NL
Hereditary angioedema types I
and II
NL NL ↓ ↓ (type I) ↓ NL NL
NL (type II)
Hereditary angioedema type III NL NL NL NL NL NL NL




NL NL NL NL NL NL NL
Idiopathic angioedema NL NL NL NL NL NL NL
Pseudoallergic angioedema NL NL NL NL NL NL NL
ACE angiotensin-converting enzyme, C3 complement factor 3, C4 complement factor 4, C1-INH C1 esterase inhibitor, NL normal.
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making the diagnosis [8].
ACE inhibitor-induced, idiopathic, and acquired
angioedema
Patients who present with attacks of angioedema due to
ACEIs will have normal levels of C4 and C1-INH
(Table 2, Figure 5) [10]. Similarly, in IAE, C4 levels along
with all other laboratory results are normal. IAE is pri-
marily a diagnosis of exclusion (Table 2, Figures 4 and 5),
In AAE, C4 levels and complement protein C1q are
reduced; C3 levels may be low or normal (Table 2) [1].
Management of acute attacks of angioedema
The international consensus from the third international
conference on HAE is that for all forms of angioedema,
airway patency is the first priority in an acute attack.
[24]. An algorithm for the management of acute angioe-
dema (duration < 6 weeks) is presented in Figure 6.
A low threshold for intubation is recommended. In-
tubation must be performed at the first sign of airway
compromise, and all cases involving laryngeal edema are
considered a medical emergency [8,14,21].
In cases of angioedema involving the tongue, oral in-
tubation is difficult at best and often impossible. Direct
fiberoptic nasotracheal intubation is the preferred
method to achieve airway patency in patients with sig-
nificant laryngeal edema. Blind nasotracheal intubation
should be avoided because of the increased potential for
localized trauma and consequent worsening of the
edema.
During an episode of acute angioedema, it may be
technically difficult to insert an endotracheal tube. If
time permits, consultation with an otolaryngologist
should be obtained for provision of a surgical airway. In
the event that all other airway methods have failed and
ENT consultation is unavailable, the emergency phys-
ician should be prepared to perform a surgical airway[1]. If attempts at nasotracheal intubation are unsuccess-
ful, cricothyrotomy or tracheotomy is indicated [6,14].
In the following sections, acute management approaches
for attacks of histamine-mediated angioedema, ACEI-
induced angioedema, and HAE, along with drug therapies
for HAE, will be addressed. Although a discussion of
prophylactic approaches to reduce the risk of subsequent
attacks is beyond the scope of this article, such approaches
should be considered for all patients following the reso-
lution of an acute attack.
Severe histamine-mediated angioedema, or anaphylaxis
The priority of the acute management of angioedema is
airway maintenance. Intramuscular (IM) epinephrine
may be used to control symptoms and sustain blood
pressure during an anaphylactic reaction; it may be life-
saving for patients with acute laryngeal edema or ana-
phylaxis [8]. Epinephrine 1:1,000 is administered IM 0.2-
0.5 mg thigh (adults); 0.01 mg/kg (up to 0.03 mg) thigh
(children). This dose can be repeated every 5–15 min-
utes, with close monitoring for signs and symptoms of
toxicity [25].
The α-adrenergic, vasoconstrictive effect of epineph-
rine reverses peripheral vasodilation, which reduces
angioedema and urticaria. The β-adrenergic properties
of epinephrine cause bronchodilation, increase myocar-
dial output and contractility, and suppress further me-
diator release from mast cells and basophils. It is
important to note that epinephrine, administered in low
concentrations (e.g., 0.1 mg/kg) is paradoxically asso-
ciated with vasodilation, hypotension, and the increased
release of inflammatory mediators. Because of the risk
for potentially lethal arrhythmias, intravenous (IV) epi-
nephrine 1:10,000 or 1:100,000 dilutions should be
administered only during cardiac arrest or to patients
who are profoundly hypotensive or have failed to re-
spond to both IV volume replacement and multiple
injections of epinephrine [25].
Physician diagnoses angioedema




Angioedema of the skin, gastrointestinal tract, or both
Unknown cause




Rule out VCD by ENT

































vomiting, diarrhea, abdominal pain
Emergency care as required
Draw blood for serum tryptase,
quantitative and functional
measurements of C4 and C1q 
components of complement
Stabilize patient and hospitalize to 
regular floor or ICU
Upon discharge refer patient to 
allergist
Known deficiency of  C1-INH
HAE less likely: 
treat as indicated
Figure 6 Algorithm for the management of patients who present with acute angioedema. C1-INH, C1 esterase inhibitor; CT, computed
tomography; ENT, ear, nose, and throat; ICU, intensive care unit; VCD, vocal cord dysfunction. Modified from [8]; with permission [PERMISSION
PENDING].
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anaphylaxis presented by severe histamine-mediated
angioedema is volume expansion. The largest catheter
possible should be inserted into the largest peripheral
vein, and the rate should be titrated to pulse and blood
pressure; infuse 1–2 l normal saline rapidly by IV in
adults (5–10 ml/kg in the first 5 min), 30 ml/kg in the
first hour in children [25].
Antihistamines act more slowly than epinephrine,
have minimal effect on blood pressure, and should not
be administered alone as treatment for anaphylaxis or
acute allergic angioedema. Combined histamine-receptor
blockade, with H1 and H2 blockers, is more effective
than the use of H1 agents alone. Diphenhydramine
should be administered 25–50 mg IV (adults), 1 mg/kg
IV up to 50 mg (children). Identical oral doses may be
sufficient for milder episodes. Ranitidine should be admi-
nistered 1 mg/kg (adults), 12.5-50 mg infused over 10 min
(children) [25,26].Inhaled β2 agonists (e.g., albuterol) are helpful when
bronchospasm resists epinephrine injections alone. Sys-
temic corticosteroids are not sufficient to prevent the
progression of anaphylaxis [25]. Although the use of a
parenteral corticosteroid (IV methylprednisolone) pro-
vides a benefit in histamine-mediated angioedema, its
therapeutic effect is not immediate.ACE inhibitor-induced angioedema
For all types of angioedema, the priority of acute man-
agement is maintenance of airway patency. Because
ACEI-induced angioedema does not involve histamine,
antihistamines have not been found to be effective in ei-
ther the acute or long-term management of these
patients; similarly, corticosteroids are not effective for
these conditions. Epinephrine should be considered to
temporarily constrict permeable blood vessels. For
patients who present with an acute attack of ACEI-
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tinuation of the ACEI [6].
The mechanism underlying ACEI-induced angioedema
(excess bradykinin) is similar to that underlying HAE.
For that reason, agents shown to be effective in HAE, in-
cluding the plasma kallikrein inhibitor ecallantide and
the bradykinin receptor antagonist icatibant, are cur-
rently being investigated in clinical studies as treatments
for acute ACEI-induced angioedema [27,28]. Several
small case studies have reported on the use of icatibant
for the treatment of ACEI-induced angioedema [29-31].
Hereditary angioedema
In May 2010, the third international conference on HAE
was held in Toronto, Canada, where international con-
sensus approaches for the diagnosis, treatment, and
management of HAE were reviewed and updated. The
consensus documents divide the therapy for patients
with HAE into acute treatment, short-term prophylaxis,
and long-term prophylaxis. The consensus recommends
that HAE attacks be treated as early as possible [24].
Patients with HAE are unlikely to respond to antihista-
mines or corticosteroids. Epinephrine has low efficacy in
HAE, but has been advocated for use early in the course
of attacks Therapeutic agents available for the treatment
of acute attacks of HAE are summarized in Table 3
[23,32-34]; see also the following discussion regarding
differential availability of these agents.
Drug therapy for hereditary angioedema
Before 2008, no drug had been approved in the US that
was predictably effective for the treatment of acute
attacks of HAE [35]. Until recently, the mainstay ofTable 3 Treatment summary of emergency care available in t
hereditary angioedema [23,32-34]
Therapy and indication Dosage
C1 esterase inhibitor [human]
(Berinert; CSL Behring)
20 U/kg body weight IV at a rate of 4
Indicated for the treatment of acute
abdominal or facial attacks of HAE in
adult and adolescent patients
Plasma kallikrein inhibitor (Kalbitor
[ecallantide]; Dyax Corp)
30 mg (3 ml) SC in three 10-mg (1 m
attack persists, additional dose of 30 m
be administered within a 24-h periodIndicated for attacks at all anatomic
sites
Fresh-frozen plasma 2 U at 1 to 12 h before the event (on
C1-INH concentrate is not available)
Bradykinin β2 receptor antagonist 30 mg (3 ml) injected SC in the abdo
attack persists, additional injections of
may be administered at intervals of ≥
than 3 injections in 24 hours
(Firazyr [icatibant]; Shire Orphan
Therapies)
Indicated for attacks at all anatomic
sites
C1-INH C1 esterase inhibitor, IV intravenously, SC subcutaneously.emergency medical treatment has been IV fresh frozen
plasma (FFP) and epsilon-aminocaproic acid [36]. Both
anecdotal and published reports suggest that FFP
replaces plasma C1-INH, thereby aborting an ongoing
attack. There is, however, a theoretical and demon-
strated increased risk of worsened swelling following ad-
ministration of FFP during an acute attack, which is
most likely due to the concurrent replacement of both
plasma proteases and substrates that are involved in the
mediation of an attack. Only anecdotal reports suggest
that epsilon-aminocaproic acid offers minimal relief dur-
ing an acute attack of HAE; however, there is no pub-
lished evidence that it provides significant benefit [5,35].
C1-INH replacement therapy
C1-INH replacement therapy functions to restore the
missing C1-INH in patients with HAE. Berinert is a
human, plasma-derived, pasteurized form of C1-INH
that was approved by the US Food and Drug Adminis-
tration (FDA) in 2009 for the treatment of acute abdom-
inal, facial, and, more recently, laryngeal attacks of HAE
in adult and adolescent patients [32]. C1-INH concen-
trate has been available in Europe for more than 20
years and is considered the standard of care for the
treatment of HAE in many countries. Pasteurized and
nanofiltered C1-INH is provided as a single-use vial that
contains 500 units of C1 esterase inhibitor as a lyophi-
lized concentrate. Each vial must be reconstituted with
10 mL of diluent (sterile water) provided. C1-INH con-
centrate must be administered using aseptic technique
at a dose of 20 units per kilogram of body weight by IV
injection (Table 3) [32,37]. Recently, the FDA has
approved self-administration of Berinert by patients.he US to patients experiencing acute attacks of
Monitoring tests
ml/ minute • Monitor patients with known risk factors for
thrombotic events
• Epinephrine should be immediately available to treat
any acute severe hypersensitivity reactions following
discontinuation of administration
l) injections. If
g (3 ml) may
• Given the similarity in hypersensitivity symptoms
and acute HAE symptoms, monitor patients closely
for hypersensitivity reactions
• Administer in a setting equipped to manage
anaphylaxis and HAE
ly for use when • Baseline: liver function tests, hepatitis virology
minal area. If
30 mg (3 ml)
6 h. No more
For patients who never received Firazyr previously,
the first treatment should be given in a medical
institution or under the guidance of a physician
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In 2009, the FDA granted approval to ecallantide (Kalbi-
tor), for the treatment of acute attacks of HAE in
patients 16 years of age and older [33]. However, the
European Union (EU) recently rendered a negative opin-
ion regarding its approval. Ecallantide is a plasma kallik-
rein inhibitor that is effective against attacks of HAE at
any anatomic location, including abdominal/gastrointes-
tinal, laryngeal, and peripheral attacks (Table 3). Ecallan-
tide binds to plasma kallikrein and blocks its binding
site, inhibiting the conversion of HMWK to bradykinin.
By directly inhibiting plasma kallikrein, ecallantide
reduces the conversion of HMWK to bradykinin and
thereby treats symptoms that occur during acute epi-
sodic attacks of HAE.
Two randomized placebo-controlled trials demon-
strated that a 30 mg subcutaneous dose of ecallantide
significantly reduced the duration of symptoms in
patients with HAE [38,39]. The most commonly
reported adverse events were headache (8%), nausea
(5%), and diarrhea (4%) [38]. Because of the 2.9% inci-
dence of anaphylaxis observed in clinical trials, the FDA
has given ecallantide a black box warning, which
requires the drug to be administered by a trained health-
care professional with emergency therapy readily avail-
able to treat an allergic reaction should one occur [33].
Bradykinin receptor antagonist
The bradykinin receptor blocker icatibant (Firazyr) (30 mg
injected subcutaneously) is a synthetic, 10 amino acid,
short-acting, and highly selective competitive bradykinin
β2 receptor antagonist [34,38,40]. Three trials have
examined the safety and efficacy of icatibant in HAE
[41,42]. These studies showed a decrease in median time
to clinically significant symptom relief. This decrease
was statistically significant in the For Angioedema Sub-
cutaneous Treatment (FAST)-2 and FAST-3 trials
[41,42]. Adverse reactions consisted of injection site
reactions in more than 90% of subjects, pyrexia, and ele-
vated transaminase levels [41,42]. No anaphylaxis was
reported. Since bradykinin is thought to play a major
role in the antihypertensive effect of ACE inhibitors, the
icatibant package insert reports that any bradykinin β2
receptor antagonist has the potential to attenuate the
antihypertensive effect of ACEIs [34].
Treatment variations by region and country
Because certain treatment options may be licensed in
some countries but not in others, the treatment of HAE
differs across countries. Phase III clinical trials are on-
going in the US for specific agents, and the standard of
care for the treatment of HAE will continue to evolve as
data from these trials become available. Rigorous phase
IV clinical trials will further delineate the long-termsafety and efficacy of the differing treatments. Data from
all trials will be used to update international and na-
tional HAE databases and registries [43].
Icatibant is approved for the treatment of acute attacks
of HAE in the EU and the US. The recent FDA indica-
tion for icatibant allows patients with HAE aged 18 years
or older to self-administer the medication [8,43].
Another difference across countries regarding the
treatment of HAE is the use of a recombinant C1-INH
(conestat alfa, Rhucin), which is produced in transgenic
rabbit milk. Recombinant C1-INH is currently under
FDA review; in June 2010, the Committee for Medicinal
Products for Human Use of the European Medicines
Agency delivered a positive opinion on the use of re-
combinant C1-INH for the treatment of acute attacks in
patients with HAE [43].
Regardless of the agent selected for acute attacks of HAE,
the patient and/or healthcare provider needs to be able to
differentiate the progression of an HAE attack from that of
an allergic reaction, as there are many similar features, so
that erroneous treatments are not provided and erroneous
diagnoses are not made. Furthermore, patients trained to
self-administer these agents should be advised that if they
are experiencing facial, neck, and/or throat swelling, they
should go to the closest emergency department for obser-
vation after taking their HAE medication.
Conclusions
The advent of innovative pharmacologic treatment
options for acute angioedema, catalyzed by an improved
understanding of pathophysiologic processes, has made
possible disease-specific therapies that have a positive
impact on morbidity and mortality. The ability of the
emergency department physician to rapidly differentiate
between the various forms of angioedema is paramount
to the successful implementation of appropriate treat-
ment for these patients.
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